Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERCULES: Phase 3 randomized double-blind study of SAR442168 (tolebrutinib) vs placebo in nonrelapsing secondary progressive multiple sclerosis
jRCT2031200240Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Tolebrutinib once daily with Placebo once daily (2 arms). Primary endpoint: 6-month confirmed disability progression (CDP). Started Apr 2021; status: completed.
02
Drugs
tolebrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on jRCT2031200240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200240.